Shuailiang Lin, PhD
Associate Director, Translational Sciences
Shuailiang Lin is the Associate Director of Translational Sciences at Kriya Therapeutics. Dr. Lin joins Kriya from Ligandal Inc., where he was the Director of Genome Editing and built and led the team of gene editing, gene delivery and TCR engineering in T cells. Dr. Lin was part of the early development team and a co-inventor of CRISPR/Cas9 genome engineering system in Feng Zhang’s lab at The Broad Institute. Beyond gene editing, Dr. Lin has also applied the CRISPR system in gene regulation in vivo at Harvard Medical School and human genome-wide screen at UCSF. Dr. Lin has more than ten years of experiences in genome engineering and gene delivery.
Dr. Lin received his PhD at Tsinghua University and completed his postdoctoral fellowship at the University of California, San Francisco. Dr. Lin received his undergraduate degree in Biological Sciences from the China Agricultural University.